Loading...
•
Sep 30, 2022
CRISPR Therapeutics Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022.
Key Takeaways
CRISPR Therapeutics reported its Q3 2022 financial results, highlighting progress in its clinical pipeline, including exa-cel's regulatory submissions and advancements in immuno-oncology and regenerative medicine programs.
Exa-cel submission to the FDA for rolling review expected to begin in November, with completion expected in Q1 2023.
EMA and MHRA submissions for exa-cel are on track for Q4 2022.
Enrollment and dosing are ongoing for CTX110 and CTX130, with additional data expected in 2022.
IND cleared by the FDA for CTX112, and CTA cleared by Health Canada for VCTX211.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...